About this trial
This study looks at a new way to treat advanced or recurring retinoblastoma, a type of eye cancer in children. The research will test a special device that delivers chemotherapy directly to the eye. The goal is to find out how safe this treatment is and how well it works to help save the affected eye.
The trial's ID number is NCT06679634. It is a Phase 2 study, which means it is testing the treatment's effectiveness and safety. About 30 children are expected to participate, and the treatment is regulated by the FDA.
Who can join
Children under 8 years old who have certain types of retinoblastoma and have had previous treatments may join. They need to have some vision in the affected eye and meet health criteria. The trial team will confirm eligibility for each participant before they can join.
The study team makes the final call on eligibility.
What happens in the study
Participants will receive a treatment called Chemoplaque (Episcleral Topotecan). This involves placing a device in the eye during a minor surgery. It will release chemotherapy for 8 weeks. Everyone in the study will receive this treatment, and researchers will monitor their progress over 12 weeks.
Where
This trial is running at 2 locations in the United States. All of them are currently recruiting.
Children's Wisconsin
Milwaukee, Wisconsin
NewYork Presbyterian Morgan Stanley Children's Hospital
New York, New York